A peptide MC1R antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

MSG606 (trifluoroacetate salt)

Item No. 41550

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-(4-mercapto-1-oxobutyl)glycyl-L-histidyl-D-phenylalanyl-L-arginyl-D-tryptophyl-L-cysteinyl-L-α-aspartyl-L-arginyl-L-phenylalanyl-glycinamide, cyclic (1→6)-thioether, trifluoroacetate salt
Synonyms
  • cyclo(CH2)3CO-Gly-His-D-Phe-Arg-D-Trp-Cys)-Asp-Arg-Phe-Gly-NH2
Molecular Formula
C62H82N20O13S • XCF3COOH
Formula Weight
1347.5
Purity
≥95%
Formulation (Request formulation change)
A solid
Peptide Sequence
c(XGHfRwC)DRFG-NH2 (where X = C3H6-CO)
Solubility(Learn about Variance in Solubility)
Acetonitrile: Slightly soluble: 0.1-1 mg/mlDMSO: Sparingly soluble: 1-10 mg/mlWater: Slightly soluble: 0.1-1 mg/ml
SMILES
O=C([C@@H](NC([C@H](NC([C@@H](NC(CNC(CCCSC[C@H](NC1=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(NCC(N)=O)=O)CC2=CC=CC=C2)=O)=O)=O)=O)=O)CC3=CN=CN3)=O)CC4=CC=CC=C4)=O)CCCNC(N)=N)N[C@@H]1CC5=CNC6=CC=CC=C56.O=C(O)C(F)(F)F
InChi Code
InChI=1S/C62H82N20O13S.C2HF3O2/c63-49(83)31-73-53(88)43(24-35-12-3-1-4-13-35)78-54(89)41(18-9-21-69-61(64)65)77-59(94)47(28-52(86)87)81-60(95)48-33-96-23-11-20-50(84)72-32-51(85)75-46(27-38-30-68-34-74-38)58(93)79-44(25-36-14-5-2-6-15-36)56(91)76-42(19-10-22-70-62(66)67)55(90)80-45(57(92)82-48)26-37-29-71-40-17-8-7-16-39(37)40;3-2(4,5)1(6)7/h1-8,12-17,29-30,34,41-48,71H,9-11,18-28,31-33H2,(H2,63,83)(H,68,74)(H,72,84)(H,73,88)(H,75,85)(H,76,91)(H,77,94)(H,78,89)(H,79,93)(H,80,90)(H,81,95)(H,82,92)(H,86,87)(H4,64,65,69)(H4,66,67,70);(H,6,7)/t41-,42-,43-,44+,45+,46-,47-,48-;/m0./s1
InChi Key
FNRWRBZUAMZCEI-ZXLAOGNBSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $87

    Add

    1 mg

    $165

    Add

    5 mg

    $522

    Add

    10 mg

    $869

    Add
    Product Description

    MSG606 is a peptide antagonist of melanocortin receptor 1 (MC1R; IC50 = 17 nM for the human receptor) and a derivative of γ-melanocyte-stimulating hormone (γ-MSH).1 It selectively binds to MC1R over MC3R and MC5R (IC50s = 3,900 and 1,000 nM, respectively, for the human receptors), as well as MC4R at 10 µM. Intracerebroventricular administration of MSG606 (7.5 µg/animal) increases the latency to tail withdrawal in the tail-flick test in female, but not male, mice in a model of opioid-induced hyperalgesia.2 MSG606 (1 nmol/animal, i.c.v.) reduces levels of the tumor suppressor protein merlin in the cortex, reduces the number of surviving neurons in the cortex and hippocampal CA2 region, and increases the number of apoptotic cells in the cortex in rats 24 hours after injury in a model of controlled cortical impact-induced traumatic brain injury (TBI).3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Cai, M., Stankova, M., Muthu, D., et al. An unusual conformation of γ-melanocyte-stimulating hormone analogues leads to a selective human melanocortin 1 receptor antagonist for targeting melanoma cells. Biochemistry 52(4), 752-764 (2013).

    2. Juni, A., Cai, M., Stankova, M., et al. Sex-specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor. Anesthesiology 112(1), 181-188 (2010).

    3. Lu, J., Wang, J., Ni, H., et al. Activation of the melanocortin-1 receptor attenuates neuronal apoptosis after traumatic brain injury by upregulating Merlin expression. Brain Res. Bull. 207:110870, (2024).